Scilex Holding Company
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsScilex Holding Co. is a commercial-stage biopharmaceutical company focused on non-opioid pain management products, with three marketed drugs and a new cryptocurrency treasury strategy.
What they do
Scilex acquires, develops, and commercializes non-opioid pain management products. Its commercial portfolio includes ZTlido (lidocaine topical system for postherpetic neuralgia), ELYXYB (oral solution for acute migraine), and GLOPERBA (liquid colchicine for gout flares, launched June 2024). The company also has three product candidates in development: SEMDEXA (sciatica, Phase 3 completed), SP-103 (acute low back pain, Phase 2 completed), and SP-104 (fibromyalgia, Phase 1 completed). Scilex relies on third-party manufacturers, such as Oishi Koseido for ZTlido.
Revenue drivers
- ZTlido — Prescription lidocaine topical system for postherpetic neuralgia; launched 2018, manufactured by Oishi Koseido in Japan; a key commercial product.
- ELYXYB — Only FDA-approved ready-to-use oral solution for acute migraine with or without aura; first-line potential treatment.
- GLOPERBA — First and only liquid oral colchicine for prophylaxis of gout flares; launched June 2024, contributing to recent revenue.
Recent performance
Annual revenue grew steadily from $31.3M in 2021 to $56.6M in 2024, but fell sharply to $30.3M in 2025. Net loss widened dramatically to $374.1M in 2025, with diluted EPS of -$36.48. Quarterly revenue was mixed: $9.9M (Q2 2025), $10.6M (Q3 2025), $4.8M (Q4 2025), and $8.6M (Q1 2026). As of March 31, 2026, the company had cash of $3.4M, total assets of $293.6M, total liabilities of $547.7M, and negative shareholder equity of -$249.2M. Operating cash flow turned positive in 2024 at $19.3M, but dropped to $3.8M in 2025.
Strategy
Scilex intends to grow its non-opioid pain portfolio and advance pipeline candidates through FDA approval. Additionally, the company has adopted a cryptocurrency treasury strategy, planning to invest in bitcoin, Ethereum, and other cryptocurrencies as long-term assets, and to generate revenue through staking and yield activities. It also considers strategic acquisitions of companies aligned with this crypto strategy. No further details on product-specific strategic initiatives were disclosed in the provided excerpts.
Risks
- Liquidity risk — Cash of $3.4M as of March 31, 2026, versus total liabilities of $547.7M, indicating potential near-term funding needs.
- Negative equity — Shareholder equity was -$249.2M as of March 31, 2026, reflecting accumulated losses and potential going-concern issues.
- Revenue volatility — Quarterly revenue dropped from $10.6M in Q3 2025 to $4.8M in Q4 2025, and annual revenue fell by nearly half in 2025.
- Manufacturing concentration — ZTlido reliance on a single supplier (Oishi Koseido) under exclusive agreements exposes the company to supply chain disruptions.
Outlook
Management has not provided explicit forward guidance in the supplied excerpts. The company is focused on advancing SEMDEXA and other pipeline candidates toward approval. The new cryptocurrency treasury strategy indicates a shift in capital allocation that may support future revenue diversification. However, the company's financial position suggests ongoing reliance on external financing to meet obligations.